Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Neuroblastoma (paediatric), drawn from the whole corpus: 37 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Relapsed high-risk disease.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Long-term toxicity of intensive therapy.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Relapsed high-risk neuroblastoma is rarely curable; MYCN-amplified relapse worst of all.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Anti-GD2 therapy causes severe neuropathic pain; less painful antibody formats (e.g., humanised, Fc-engineered) and CAR-T are needed.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Long-term toxicity of tandem transplant, cisplatin (hearing loss), and radiation in children who will live 70 years.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Eflornithine's approval rests on an external control; a randomised trial is unlikely, so uncertainty persists.
Access: anti-GD2 antibodies are expensive and unavailable in most low- and middle-income countries where most children with cancer live.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
MYCN remains undruggable directly; polyamine and Aurora/BET strategies are indirect.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Targets · KRAS roadmap.
GD2 CAR-T needs randomised evidence and manufacturing at scale; only a few centres can deliver it.
Imaging burden: repeated MIBG scans with sedation; MFBG PET adoption is slow.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 38 changes by month →When this page itself was last checked or edited.
Tandem autologous transplant (thiotepa-cyclophosphamide, then CEM) in North America (ANBL0532); single busulfan-melphalan transplant in Europe (HR-NBL1). (NCCN COG standard (tandem); SIOPEN standard (BuMel))
Anti-GD2 antibody (dinutuximab + GM-CSF + isotretinoin; dinutuximab beta in Europe, no IL-2) × 5-6 cycles; then eflornithine maintenance 2 years (US, 2023). (NCCN Dinutuximab: FDA-approved standard; eflornithine: FDA-approved maintenance)
5-6 cycles (COG: topotecan-cyclophosphamide × 2 then cisplatin-etoposide, cyclophosphamide-doxorubicin-vincristine; SIOPEN: rapid COJEC); stem-cell harvest; ANBL1531 adds 131I-MIBG (randomised) or lorlatinib (ALK); ANBL17P1 adds dinutuximab to induction. (NCCN COG ANBL1531 backbone)
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.